Literature DB >> 26998170

Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide.

Weiling Sun1, Chunhong Li2, Meiyan Liu2, Wei Liu2, Chunyu Yang2, L I Cai2.   

Abstract

The aim of the present study was to investigate the association between the clinicopathological and demographic factors, and the survival time of patients with triple-negative breast cancer (TNBC) in China. The patients had received adjuvant chemotherapy consisting of 5-fluorouracil, epirubicin and cyclophosphamide (FEC; 500 mg/m2 cyclophosphamide, day 1; 75 mg/m2 epirubicin, day 1; 500 mg/m2 5-fluorouracil, days 1 and 8; every 3 weeks, for at least 4 cycles). The clinicopathological and demographic factors affecting the outcome of the patients with TNBC that received adjuvant FEC chemotherapy were evaluated. Within these variables, the overall survival (OS) and disease-free survival (DFS) times were analyzed using the log-rank test, which was constructed using the multivariate Cox proportional hazards regression model and Kaplan-Meier analysis. Additionally, Spearman's χ2 test was used to analyze categorical variables. In the univariate statistical analysis, the significant risk factors for TNBC patient survival were the stage of disease and lymph node status, which were associated with the OS and DFS, and the total number of pregnancies, which was associated with the DFS. In the multivariate Cox proportional hazard model, lymph node status was an independent prognostic indicator of OS [P<0.001; hazard ratio (HR), 1.996; 95% confidence interval (CI), 1.465-2.720] and DFS (P<0.001; HR, 1.824; 95% CI, 1.315-2.531). By the Kaplan-Meier method, the stage of disease and lymph node status demonstrated a significant effect on OS and DFS. Patients with the lymph node status N3 and stage III disease possessed a poor prognosis and survival. An association between lymph node status and the tumor recurrence and mortality rate was identified. The area under the curves of the lymph node status for TNBC recurrence and mortality were 0.676 (P=0.002) and 0.685 (P=0.001), respectively. Additionally, the number of pregnancies was associated with tumor size, lymph node status and stages of disease. Lymph node status is an independent prognostic indicator of OS and DFS to TNBC patients with FEC adjuvant chemotherapy.

Entities:  

Keywords:  cyclophosphamide; disease-free survival; epirubicin; fluorouracil; lymph node status; overall survival; triple negative breast cancer

Year:  2016        PMID: 26998170      PMCID: PMC4774624          DOI: 10.3892/ol.2016.4176

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Authors:  Makiko Ono; Hitoshi Tsuda; Chikako Shimizu; Sohei Yamamoto; Tatsuhiro Shibata; Harukaze Yamamoto; Taizo Hirata; Kan Yonemori; Masashi Ando; Kenji Tamura; Noriyuki Katsumata; Takayuki Kinoshita; Yuichi Takiguchi; Hideki Tanzawa; Yasuhiro Fujiwara
Journal:  Breast Cancer Res Treat       Date:  2011-05-12       Impact factor: 4.872

3.  Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Authors:  Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 4.  Dissecting the heterogeneity of triple-negative breast cancer.

Authors:  Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Authors:  Socorro María Rodríguez-Pinilla; David Sarrió; Emiliano Honrado; Gema Moreno-Bueno; David Hardisson; Francisco Calero; Javier Benítez; José Palacios
Journal:  J Clin Pathol       Date:  2006-11-14       Impact factor: 3.411

6.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Emmanuelle Charafe-Jauffret; Emilie Mamessier; José Adélaïde; Stéphane Debono; Gilles Houvenaeghel; Dominique Maraninchi; Patrice Viens; Colette Charpin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

7.  The prognostic importance of triple negative breast carcinoma.

Authors:  Hakan Mersin; Emin Yildirim; Ugur Berberoglu; Kaptan Gülben
Journal:  Breast       Date:  2008-05-01       Impact factor: 4.380

8.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 9.  What is triple-negative breast cancer?

Authors:  William J Irvin; Lisa A Carey
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

10.  Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

Authors:  Harri Sihto; Johan Lundin; Mikael Lundin; Tiina Lehtimäki; Ari Ristimäki; Kaija Holli; Liisa Sailas; Vesa Kataja; Taina Turpeenniemi-Hujanen; Jorma Isola; Päivi Heikkilä; Heikki Joensuu
Journal:  Breast Cancer Res       Date:  2011-09-13       Impact factor: 6.466

View more
  2 in total

Review 1.  Dancing from bottoms up - Roles of the POZ-ZF transcription factor Kaiso in Cancer.

Authors:  Christina C Pierre; Shawn M Hercules; Clayton Yates; Juliet M Daniel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-09       Impact factor: 11.414

2.  MicroRNA-941 regulates the proliferation of breast cancer cells by altering histone H3 Ser 10 phosphorylation.

Authors:  Sunil Kumar Surapaneni; Zahid Rafiq Bhat; Kulbhushan Tikoo
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.